Clinical Trials Logo

Diabetes Mellitus, Type 2 clinical trials

View clinical trials related to Diabetes Mellitus, Type 2.

Filter by:

NCT ID: NCT00782639 Terminated - Diabetes Mellitus Clinical Trials

Renal Safety of Iopamidol Versus Iodixanol During Coronary Angiography in Diabetic Patients

RECARE
Start date: March 2009
Phase: Phase 4
Study type: Interventional

The purpose of this study is to compare the incidence of contrast-induced nephropathy (CIN) following the administration of iopamidol-370 (Iopamiro-370) and iodixanol-320 (Visipaque 320) in patients with moderate-to-severe chronic kidney disease and diabetes mellitus undergoing cardiac angiography.

NCT ID: NCT00767000 Terminated - Clinical trials for Diabetes Mellitus, Type 2

Dose Range Finding Study of MK-0941 in Patients With Type 2 Diabetes Mellitus on Insulin (MK-0941-007 AM3 EXT1 AM1)(TERMINATED)

Start date: October 2008
Phase: Phase 2
Study type: Interventional

The purpose of this study is to test the effect of MK-0941 as add-on therapy for participants taking insulin for type 2 diabetes mellitus. The primary hypotheses of this study are that treatment with MK-0941 added to insulin will provide greater reduction in hemoglobin A1c (HbA1c) level than will placebo added to insulin at 14 weeks, and that MK-0941 will be well-tolerated at 1 or more doses that demonstrate efficacy.

NCT ID: NCT00766441 Terminated - Diabetes Clinical Trials

Sitagliptin Versus Sulphonylurea in Type 2 Diabetes During Ramadan

Start date: August 2008
Phase: Phase 4
Study type: Interventional

This study will assess if Sitagliptin addition to metformin or glitazone is better than current sulphonylurea based treatments during Ramadan. The rationale is that Sitagliptin offers metabolic advantages primarily with the low incidence of hypoglycemia over current sulphonylurea based treatments.

NCT ID: NCT00763347 Terminated - Diabetes Mellitus Clinical Trials

Efficacy and Safety Study of SYR-619 in Treating Subjects With Type 2 Diabetes Mellitus

Start date: November 2006
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the efficacy and safety of SYR-619, once daily (QD), in subjects with type 2 diabetes mellitus who have not achieved glycemic control with diet and exercise, or by taking metformin.

NCT ID: NCT00762957 Terminated - Diabetes Mellitus Clinical Trials

Safety and Efficacy of TAK-559 in Combination With Metformin in Patients With Type 2 Diabetes Mellitus.

Start date: November 2004
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of TAK-559, once daily (QD), taken in combination with metformin in treating subjects with type 2 diabetes mellitus

NCT ID: NCT00762684 Terminated - Diabetes Mellitus Clinical Trials

Efficacy and Safety Study of TAK-559 in Treating Subjects With Type 2 Diabetes Mellitus

Start date: November 2004
Phase: Phase 3
Study type: Interventional

The purpose of this study was to determine the safety and efficacy of TAK-559, once daily (QD), in treating subjects with type 2 diabetes mellitus.

NCT ID: NCT00762190 Terminated - Diabetes Mellitus Clinical Trials

Study of TAK-559 in Treating Subjects With Type 2 Diabetes Mellitus

Start date: November 2003
Phase: Phase 3
Study type: Interventional

The purpose of this study was to determine the safety of TAK-559, once daily (QD), in treating subjects receiving a stable dose of insulin to control type 2 diabetes mellitus.

NCT ID: NCT00762112 Terminated - Diabetes Mellitus Clinical Trials

Safety Study of TAK-559 in Treating Subjects With Type 2 Diabetes Mellitus

Start date: November 2003
Phase: Phase 3
Study type: Interventional

The purpose of this study was to determine the long-term safety of TAK-559, once daily (QD), in subjects with Type 2 Diabetes.

NCT ID: NCT00759720 Terminated - Diabetes Mellitus Clinical Trials

Efficacy and Safety of TAK-559 Combined With Glyburide in Treating Subjects With Type 2 Diabetes Mellitus.

ORIGAMI
Start date: November 2003
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine the safety and efficacy of TAK-559, once daily (QD), combined with glyburide in treating Type 2 Diabetes.

NCT ID: NCT00754689 Terminated - Clinical trials for Diabetes Mellitus, Type 2

Study of Rimonabant/Metformin Combinations to Investigate Diabetes (Blood Sugar) Control in Patients With Type 2 Diabetes

Start date: September 2008
Phase: Phase 3
Study type: Interventional

The primary objective of the study is to demonstrate superiority of rimonabant/metformin combinations in A1C reduction over the corresponding single agent metformin and over rimonabant alone in patients with type 2 diabetes mellitus at 9 months. The secondary objective of the study is to investigate the effects of rimonabant/metformin combinations for reducing fasted plasma glucose, body weight and triglycerides, and raising HDL-C in comparison with metformin at 9 months. Another study objective is to evaluate the safety of rimonabant in combination with metformin over a period of up to 52 weeks.